ClinicalTrials.gg

Program

CBL-514

A development code. Also written as “CBL-514 Injection”, “CBL-514 injection” and “40 mg CBL-514”.

Its studies are mostly in Cellulite · Lipedema, led by Caliway Biopharmaceuticals.

Furthest: phase 3, since Aug 21, 202516 company-led studies, 5 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Caliway Biopharmaceuticals165 open or runningphase 3since Aug 21, 2025Aug 19, 2020Apr 2027phase 2 · NCT07608770

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Aug 19, 2020.

  1. Dec 29, 2020Phase 1 study in Subcutaneous FatNCT04699669 · 40 enrolled · Australia
  2. Dec 29, 2020Phase 2 study in Subcutaneous FatNCT04698642 · 43 enrolled · Australia
  3. May 18, 2021Phase 2 study in Subcutaneous FatNCT04897412 · 75 enrolled · United States, Australia
  4. Dec 23, 2021Phase 2 study in Subcutaneous FatNCT05234736 · 10 enrolled · United States
  5. May 19, 2022Phase 2 study in Adiposis DolorosaNCT05387733 · 12 enrolled · United States
  6. Nov 21, 2022Phase 2 study in CelluliteNCT05632926 · 12 enrolled · United States
  7. Feb 10, 2023Phase 2 study in Subcutaneous FatNCT05736107 · 107 enrolled · United States
  8. Apr 19, 2023Phase 2 study in CelluliteNCT05836779 · 23 enrolled · United States
  9. Aug 10, 2023Phase 2 study in Subcutaneous FatNCT06005441 · 173 enrolled · United States
  10. Feb 26, 2024Phase 2 study in Adiposis DolorosaNCT06303570 · 19 enrolled · United States
  11. Aug 21, 2025Phase 3 study in Subcutaneous FatNCT07140939 · 320 planned · United States, Canada
  12. Apr 8, 2026Phase 3 study in Subcutaneous FatNCT07526974 · 320 planned · United States, Australia, Canada
  13. May 19, 20262 phase 2 studies in Subcutaneous FatNCT07608770, NCT07608757
  14. Jul 24, 2026Phase 3 study in Subcutaneous FatNCT07733947 · 300 planned · United States

Ahead

  1. Apr 2027Primary completion: phase 2 study in Subcutaneous FatNCT07608770
  2. Jul 2027Primary completion: phase 3 study in Subcutaneous FatNCT07140939
  3. Aug 2027Primary completion: phase 3 study in Subcutaneous FatNCT07526974
  4. Feb 2028Primary completion: phase 2 study in Subcutaneous FatNCT07608757

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07733947Subcutaneous Fat · United States3Not yet recruitingAug 2028300
NCT07608757Subcutaneous Fat · Australia2Not yet recruitingFeb 2028250
NCT07608770Subcutaneous Fat · Australia2RecruitingApr 2027250
NCT07526974Subcutaneous Fat · United States, Australia, Canada3Not yet recruitingAug 2027320
NCT07140939Subcutaneous Fat · United States, Canada3RecruitingJul 2027320
NCT06303570Adiposis Dolorosa · United States2CompletedMar 23, 202619
NCT06005441Subcutaneous Fat · United States2CompletedOct 18, 2024173
NCT05836779Cellulite · United States2CompletedNov 29, 202323
NCT05736107Subcutaneous Fat · United States2CompletedMay 20, 2024107
NCT05632926Cellulite · United States2CompletedMay 3, 202312
NCT05387733Adiposis Dolorosa · United States2CompletedApr 3, 202312
NCT05234736Subcutaneous Fat · United States2CompletedJun 9, 202210
NCT04897412Subcutaneous Fat · United States, Australia2CompletedFeb 22, 202375
NCT04699669Subcutaneous Fat · Australia1CompletedAug 20, 201940
NCT04698642Subcutaneous Fat · Australia2CompletedNov 12, 202043
NCT04575467Subcutaneous Fat · Australia2CompletedNov 15, 202125

How it is read

Names in the registry

  • “CBL-514 Injection”, 7 entries
  • “CBL-514”, 4 entries
  • “CBL-514 injection”, 3 entries
  • “40 mg CBL-514”, 1 entry
  • “60 mg CBL-514”, 1 entry

Codes read as this program: CBL514.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.